Valentina V. Ignatova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Valentina V. Ignatova has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Adrián Sanz-Moreno
Institute of Experimental Genetics, German Mouse Clinic, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
1 shared publication - Andrea Pavesi
Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore, Singapore
1 shared publication Birgit Rathkolb
German Mouse Clinic, Institute of Experimental Genetics, Helmholtz Zentrum München, 85764 Neuherberg, Germany
1 shared publication- Chee Leng Lee
Monash Institute of Pharmaceutical Sciences, Monash University, 399 Royal Parade, Parkville VIC 3052, Australia
1 shared publication Emil Ibragimov
Institute of Functional Epigenetics, Helmholtz Zentrum München, 85764 Neuherberg, Germany
1 shared publication- Ernesto Guccione
Center of OncoGenomics and Innovative Therapeutics (COGIT), Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
1 shared publication
Latest Publications
- Open Access
- 28 August 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (35) , eaaz4551
METTL6 is a tRNA m 3 C methyltransferase that regulates pluripotency and tumor cell growth
Recently, covalent modifications of RNA, such as methylation, have emerged as key regulators of all aspects of RNA biology and have been implicated in numerous diseases, for instance, cancer. Here, we undertook a combination of in vitro and in vivo screens to test 78 potential methyltransferases for their roles in hepatocellular carcinoma (HCC) cell proliferation. We identified methyltransferase-like protein 6 (METTL6) as a crucial regulator of tumor cell growth. We show that METTL6 is a bona fide transfer RNA (tRNA) methyltransferase, catalyzing the formation of 3-methylcytidine at C32 of specific serine tRNA isoacceptors. Deletion of Mettl6 in mouse stem cells results in changes in ribosome occupancy and RNA levels, as well as impaired pluripotency. In mice, Mettl6 knockout results in reduced energy expenditure. We reveal a previously unknown pathway in the maintenance of translation efficiency with a role in maintaining stem cell self-renewal, as well as impacting tumor cell growth profoundly.
- 28 August 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (35) , eaaz4551
Open AccessMETTL6 is a tRNA m 3 C methyltransferase that regulates pluripotency and tumor cell growth
Recently, covalent modifications of RNA, such as methylation, have emerged as key regulators of all aspects of RNA biology and have been implicated in numerous diseases, for instance, cancer. Here, we undertook a combination of in vitro and in vivo screens to test 78 potential methyltransferases for their roles in hepatocellular carcinoma (HCC) cell proliferation. We identified methyltransferase-like protein 6 (METTL6) as a crucial regulator of tumor cell growth. We show that METTL6 is a bona fide transfer RNA (tRNA) methyltransferase, catalyzing the formation of 3-methylcytidine at C32 of specific serine tRNA isoacceptors. Deletion of Mettl6 in mouse stem cells results in changes in ribosome occupancy and RNA levels, as well as impaired pluripotency. In mice, Mettl6 knockout results in reduced energy expenditure. We reveal a previously unknown pathway in the maintenance of translation efficiency with a role in maintaining stem cell self-renewal, as well as impacting tumor cell growth profoundly.